Literature DB >> 15161322

Improved targeting of photosensitizers by intratumoral administration of immunoconjugates.

Seema Gupta1, A K Mishra, K Muralidhar, Viney Jain.   

Abstract

Biodistribution of technetium (99mTc) labeled hematoporphyrin derivative (HpD, Photosan-3) conjugated to a monoclonal antibody to carcinoembryonic antigen (anti-CEA) was compared following intravenous (i.v.) and intratumoral (i.t.) administration in solid Ehrlich ascites tumor bearing mice. Images of mice at different time intervals were acquired after injection of radiolabeled PS-3 in either conjugated or unconjugated forms. Quantitative estimation of the radiolabel in different tissues was performed by selecting the different region of interests (ROIs). Maximum accumulation of both free and antibody conjugated PS-3 following i.v. administration was observed in liver followed by tumor. Tumor/muscle (T/N) ratio was more with free PS-3 compared to conjugated PS-3. Pharmacokinetics of free and conjugated PS-3 was also different with faster accumulation of conjugated PS-3 in the tumor. With intratumoral administration of anti-CEA-PS-3-99mTc, specific accumulation and retention of the sensitizer was observed in the tumor tissue. Since, direct injection of antibody conjugated photosensitizer into the tumor resulted in longer retention of the dye in the tumor with no accumulation in the normal tissues, the present results imply that the toxicity to normal tissues could be reduced significantly with selective destruction of the tumor following photodynamic treatment with the use of i.t. administration of specific antibodies conjugated to photosensitizers.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15161322     DOI: 10.1177/153303460400300307

Source DB:  PubMed          Journal:  Technol Cancer Res Treat        ISSN: 1533-0338


  4 in total

1.  Macrophage-targeted photosensitizer conjugate delivered by intratumoral injection.

Authors:  Florencia Anatelli; Pawel Mroz; Qingde Liu; Changming Yang; Ana P Castano; Emilia Swietlik; Michael R Hamblin
Journal:  Mol Pharm       Date:  2006 Nov-Dec       Impact factor: 4.939

2.  Intratumoral Photosensitizer Delivery and Photodynamic Therapy.

Authors:  Chen-Hua Ma; Jeffrey Yang; Jenna L Mueller; Huang-Chiao Huang
Journal:  Nano Life       Date:  2021-06-09

Review 3.  Combination of photodynamic therapy and immunomodulation: current status and future trends.

Authors:  Yong-Gang Qiang; Christine M N Yow; Zheng Huang
Journal:  Med Res Rev       Date:  2008-07       Impact factor: 12.944

4.  In vitro and in vivo matrix metalloproteinase expression after photodynamic therapy with a liposomal formulation of aminolevulinic acid and its methyl ester.

Authors:  Beata Osiecka; Kamil Jurczyszyn; Krzysztof Symonowicz; Andrzej Bronowicz; Paweł Ostasiewicz; Elzbieta Czapińska; Katarzyna Hotowy; Małgorzata Krzystek-Korpacka; Elzbieta Gebarowska; Ilona Izykowska; Piotr Dziegiel; Grzegorz Terlecki; Piotr Ziółkowski
Journal:  Cell Mol Biol Lett       Date:  2010-09-17       Impact factor: 5.787

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.